Mitigating Brexit Risks in Pharma Supply Chain
A leading pharmaceutical company needed to adapt its supply chain strategy to mitigate disruption risks caused by Brexit, which impacted clinical trials and logistics operations in the UK. To maintain uninterrupted global medication supply, the company sought a resilient distribution and storage solution that could navigate the evolving regulatory and logistical landscape post-Brexit.
Ambition: securing supply chain continuity in a post-Brexit landscape
Brexit introduced political uncertainty and shifting trade regulations, creating challenges in maintaining smooth supply chain operations. The company recognized the need to safeguard clinical trials and secure reliable medication delivery by proactively adjusting to new trade agreements and regulatory requirements. Additionally, aligning operations with a revised distribution strategy was essential to ensuring timely and efficient supply across global markets.
How we helped
We helped in devising a comprehensive mitigation strategy that strengthened the client’s supply chain resilience. This involved establishing a new regional depot in the EU to streamline distribution, revising stock policies, and building localized stock buffers. We supported the client in designing a tailored distribution strategy for clinical trials to minimize reliance on UK operations, reduce lead times, and strengthen supply chain stability amid Brexit-related uncertainties.
Results
The proactive strategy ensured clinical trial continuity and a steady global medication supply to patients. The new EU depot and optimized stock policies reduced lead times, while localized stock buffers improved supply reliability. This streamlined distribution model delivered a robust, adaptable solution, ensuring long-term supply resilience for patients in the post-Brexit environment.
Ready to enhance supply chain resilience amid regulatory changes? Contact us today to learn how we can help you.
